Vidaza IV Granted Priority Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmion's NDA supplement for IV administration of its demethylating agent Vidaza (azacitidine) has a Sept. 29 user fee date under a six-month review, the company announced June 13